View Older Stories View More Recent Stories

Jul 28, 2023 07:05AM Ionis Pharmaceuticals (IONS) Expands eplontersen Deal with AstraZeneca (AZN) to Include Latin America
Jul 27, 2023 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor0
Jul 3, 2023 07:00AM Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
Jun 29, 2023 09:17AM AstraZeneca (AZN) Announces IMFINZI plus IMJUDO demonstrated sustained OS benefit in advanced liver cancer
Jun 29, 2023 09:15AM IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMA
Jun 28, 2023 02:00AM AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
Jun 26, 2023 01:00AM First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Jun 26, 2023 01:00AM Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Jun 13, 2023 07:00AM AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
Jun 12, 2023 07:00AM Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
Jun 5, 2023 08:05AM Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
Jun 5, 2023 08:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
Jun 5, 2023 07:03AM AstraZeneca (AZN) Announces ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
Jun 5, 2023 07:00AM ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
Jun 5, 2023 05:57AM AstraZeneca (AZN) Announces TAGRISSO Achieves Unprecedented Survival in Early-stage EGFR-mutated Lung Cancer
Jun 4, 2023 08:00AM TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
Jun 3, 2023 08:00AM LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor
Jun 2, 2023 03:56PM AstraZeneca (AZN) Announces IMFINZI plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
Jun 2, 2023 03:56PM IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
Jun 1, 2023 07:03AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Jun 1, 2023 07:00AM LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
May 30, 2023 08:04AM Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM
May 26, 2023 07:03AM AstraZeneca (AZN) Announces IMFINZI plus LYNPARZA and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
May 26, 2023 07:00AM IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
May 25, 2023 07:00AM AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
May 23, 2023 02:15PM New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
May 18, 2023 06:00AM Revvity Announces New License Agreement for Next-Generation Base Editing Technology
May 17, 2023 07:00AM TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
May 9, 2023 11:37AM FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
Apr 24, 2023 07:00AM NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
Apr 16, 2023 11:50AM IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
Apr 11, 2023 07:00AM AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023
Mar 27, 2023 07:00AM Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
Mar 9, 2023 07:11AM AstraZeneca's (AZN) TAGRISSO demonstrated strong OS benefit in ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Mar 9, 2023 07:11AM TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Mar 9, 2023 07:08AM AstraZeneca's (AZN) IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable NSCLC
Mar 9, 2023 07:00AM IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
Mar 7, 2023 08:56AM Personalis (PSNL) will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement
Mar 7, 2023 08:55AM Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Mar 6, 2023 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Mar 2, 2023 04:28PM Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
Mar 2, 2023 09:04AM Merck (MRK) and AstraZeneca (AZN) Provide Update on US Regulatory Review of LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone
Feb 16, 2023 10:01AM Merck (MRK) and AstraZeneca (AZN) Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial
Feb 16, 2023 10:00AM AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
Feb 13, 2023 09:06AM SOPHiA GENETICS (SOPH) Expands Partnership With AstraZeneca (AZN) to Include Multimodal Approaches for Cancer Drug Development
Feb 13, 2023 09:00AM SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
Feb 2, 2023 09:01AM AstraZeneca (AZN) announces TEZSPIRE approved for self-administration in the US with a new pre-filled pen
Feb 2, 2023 09:00AM TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
Jan 23, 2023 07:00AM AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
Jan 18, 2023 09:30AM HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
View More Recent Stories View Older Stories